| Identification | Back Directory | [Name]
PKI 166 | [CAS]
187724-61-4 | [Synonyms]
PKI 166
PKI-166 >=98% (HPLC)
4-[4-[[(1R)-1-Phenylethyl]amino]-1H-pyrrolo[2,3-d]pyrimidin-
4-[4-(((R)-1-Phenylethyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol
(R)-4-[4-[(1-Phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol
Phenol, 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-
(R)-6-(4-Hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine | [Molecular Formula]
C20H18N4O | [MDL Number]
MFCD09970842 | [MOL File]
187724-61-4.mol | [Molecular Weight]
330.38 |
| Hazard Information | Back Directory | [Biological Activity]
PKI-166 is a potent, selective and orally bioactive EGFR tyrosine kinase inhibitor with IC50 of 0.7 nM. | [in vitro]
Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells.
PKI-166 (0.03 μM; 6 days) enhanced the cytotoxicity mediated by gemcitabine .
Western Blot Analysis | Cell Line: | L3.6pl cells | | Concentration: | 0.01 μM, 0.05 μM, 0.5 μM | | Incubation Time: | 1 hour | | Result: | Inhibited EGFR autophosphorylation in a dose-dependent manner. | Cell Cytotoxicity Assay | Cell Line: | L3.6pl cells | | Conce ntration: | 0.03 μM | | Incubation Time: | 6 days | | Result: | Enhanced the cytotoxicity mediated by gemcitabine. | | [in vivo]
PKI-166 (100 mg/kg; po; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.
| Animal Model: | Male athymic nude mice with L3.6pl cells xenograft (8–12 weeks) | | Dosage: | 100 mg/kg | | Administration: | Oral administration; daily; from day 7 to day 35 after xenograft | | Result: | Significantly decreased median tumor volume. | | [target]
IC50: 0.7 nM (EGFR tyrosine kinase) |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|